Clinical Trials Logo

Clinical Trial Summary

The aim of the present investigation is to evaluate the immunomodulation effect of ESIT12, a poplar-type propolis dry extract standardized in polyphenols, and its efficacy in subjects at risk of contracting upper respiratory tract infections (URTIs), during a 12-week supplementation period plus 4-week follow-up. The number of onset of upper respiratory tract infections, the symptoms severity and lasting and interferences with well-being will be assessed with WURSS-24 questionnaire. The quality of life will be assessed with the SF-36 questionnaire and a testimonial. Blood immune markers will also be assessed. Finally, long lasting benefits will additionally be evaluated 4 weeks after end of the supplementation period. The design of the study is double-blind, randomized, parallel and placebo controlled.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05598749
Study type Interventional
Source Fytexia
Contact Julien Cases
Phone +33 467 219 098
Email jcases@fytexia.com
Status Recruiting
Phase N/A
Start date December 5, 2022
Completion date July 30, 2024